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Background: A hydrophobic residue in TM7 of 
the hSLC2A9 was found to affect hexose 
transport. 
Results: Both Ile335 and Trp110 affect fructose 
trans-acceleration of urate, while only Try110 
directly affects urate transport. 
Conclusion: hSLC2A9 handles urate/fructose 
transport differently. 
Significance: This study provides further 
information of how hSLC2A9 handling its 
substrates, could be beneficial for future 
pharmaceutical treatments used in related diseases. 
 
ABSTRACT 
High blood urate levels (hyperuricemia) 
have been found to be a significant risk factor 
for cardiovascular diseases and inflammatory 
arthritis, such as hypertension and gout. 
Human glucose transporter 9 (hSLC2A9) is an 
essential protein that mainly regulates 
urate/hexose homeostasis in human kidney and 
liver. hSLC2A9 is a high affinity-low capacity 
hexose transporter and a high capacity urate 
transporter. Our previous studies identified a 
single hydrophobic residue in trans-membrane 
domain 7 of class II glucose transporters as a 
determinant of fructose transport. A mutation 
of isoleucine 335 to valine (I355V) in hSLC2A9 
can reduce fructose transport while not 
affecting glucose fluxes. This current study 
demonstrates that the I335V mutant transports 
urate similarly to the wild type hSLC2A9; 
however, I335 is necessary for urate/fructose 
trans-acceleration exchange to occur. 
Furthermore, tryptophan 110 (W110) is a 
critical site for urate transport. Two structural 
models of the Class II glucose transporters,  
hSLC2A9 and hSLC2A5, based on the crystal 
structure of hSLC2A1 (GLUT1) reveals that 
I335 (or the homologous I296 in hSLC2A5) is a 
key component for protein conformational 
changes when the protein translocates 
substrates. The hSLC2A9 model also predicted 
that W110 is a crucial site that could directly 
interact with urate during transport. Together, 
these studies confirm that hSLC2A9 transports 
both urate and fructose, but it interacts with 
them in different ways. Therefore, this study 
advances our understanding of how hSLC2A9 
mediates urate and fructose transport 
providing further information for developing 
pharmacological agents to treat hyperuricemia 
and related diseases, such as gout, hypertension 
and diabetes. 
The membrane proteins making up the 
human facilitated glucose transporter family are 
encoded by the solute carrier gene family 2A 
(SLC2A). Many of these transport hexoses down 
their concentration gradient across mammalian 
cell membranes. Currently, fourteen hSLC2As 
have been identified and subdivided into three 
classes (1-4), each associated with distinct 
substrate transport specificities. Many of these 
glucose transporter proteins are expressed 
specifically in different human tissues. For 
instance, the human glucose transporter 9 
(hSLC2A9) is found primarily in the human 
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kidney and liver (5,6). Genome wide association 
studies suggest that nucleotide polymorphisms 
within hSLC2A9 are associated with uric acid 
(urate) handling and urate related diseases in 
humans, such as gout, diabetes, and hypertension 
(7-12). 
 Initially, hSLC2A9 was shown to be a 
high affinity-low capacity glucose and fructose 
transporter; however, more recently studies have 
demonstrated that it is also a high capacity urate 
transporter, playing a key role in the handling of 
this important metabolite in humans. Detailed 
characterization of hSLC2A9 indicates that this 
transporter exhibits hexose/hexose trans-
acceleration and hexose/urate exchange across the 
cell membrane (13,14). That is, hexose on one side 
of the membrane can stimulate the unidirectional 
flow of hexose or urate from the other side of the 
membrane. This trans-acceleration exchange 
behaviour provides confirmation that hexoses and 
urate share the same transporter despite the 
observation that there is little or no competition for 
transport between these substrates (13,14). While 
trans-acceleration has been reported for a number 
of other members of this gene family, such as 
hSLC2A1, the exact mechanism for this 
interaction, particularly for hexoses and urate by 
hSLC2A9, remains unknown. 
Extensive analysis has predicted that the 
SLC2As all have twelve trans-membrane domains 
(TMs) with both carboxyl and amino termini, and 
a long loop that connects TM6 and TM7, 
presenting to the cytosol (15). The recent report by 
Deng and associates providing the first crystal 
structure for SLC2A1 has now confirmed this 
topology (16). However, some features such as an 
intracellular helical bundle (ICH) domain formed 
by the intracellular loop and which apparently 
closes the inner vestibule when the protein is in 
the outward facing conformation appears to be 
novel. TM7, long suspected to form part of the 
lining of the translocation pore with several key 
residues potentially involved in substrate binding 
and selectivity, is confirmed by this first SLC2A1 
crystal structure.   
We have previously proposed that 
residues in this pore lining helix, TM7, play key 
roles in determining substrate specificity. We have 
also shown that a single hydrophobic residue in 
the TM7 of several of the Class II glucose 
transporters, (hSLC2A5, 7, 9 and 11) and 
SLC2A2, markedly affects their ability to 
transport fructose, but not glucose (17). An early 
computer model of hSLC2A7, based on the 
glycerol-3-phosphate transporter (GlpT), predicted 
that the isoleucine residue, I314, in TM7 faces the 
aqueous pore and could potentially interact with a 
second hydrophobic residue, tryptophan (W89), on 
the other side of the pore in TM2. This interaction 
was proposed to form a substrate selectivity filter, 
which determined the ability of fructose to access 
the translocation mechanism (18). Substitution of 
the equivalent isoleucine (I296) with a valine in 
hSLC2A5 abolished fructose transport while 
having no effect on glucose transport. Similarly, 
substitution of isoleucine 335 with valine (I335V) 
in hSLC2A9 also strongly decreased fructose 
transport with glucose transport remaining 
unaffected. 
 This current study examined the 
importance of the hydrophobic residues I335 and 
W110 of hSLC2A9 for urate transport and 
urate/hexose trans-acceleration exchange. For this, 
we constructed three point mutations of hSLC2A9: 
isoleucine 335 to valine (I335V) and tryptophan 
110 to alanine (W110A) and phenylalanine 
(W110F).  The impact of these mutations on 
hSLC2A9 transport characteristics was then 
assessed after expressing the proteins in Xenopus 
oocytes by the use of radiotracer flux 
measurements and electrophysiology. We found 
that the mutation I335V has urate transport 
kinetics similar to the wild type (WT) protein; 
whereas W110A has lower capacity and higher 
affinity for urate transport compared to WT 
hSLC2A9. Wild type and mutant transporters 
exhibited urate/urate trans-acceleration; however, 
fructose/ urate trans-acceleration was lost in both 
the I335V and W110A mutants; but retained in 
W110F mutant. Immunohistochemistry and 
biotinylation studies indicated that all proteins are 
expressed at similar levels in the oocyte. This 
suggests that these functional differences between 
WT and mutant hSLC2A9 are due to structural 
changes in the protein, which is further discussed 
in light of a new structural model for hSLC2A9 
based upon the crystal structure of hSLC2A1 (16). 
 These results demonstrate that I335 of 
hSLC2A9 is necessary for urate/fructose trans-
acceleration exchange to occur. They also indicate 
that W110 of hSLC2A9 is critical for urate 
transport. Together they also confirmed that urate 
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 Plasmid construction-- Original human 
hSLC2A9 was a gift from Kelly Moley and 
inserted into the pGEM-HE vector for oocyte 
expression. Site-directed mutagenesis was 
performed by using QuikChange II site-directed 
mutagenesis kit (Stratagene) to construct 
isoleucine 335 to valine (I335V), and tryptophan 
110 to alanine (W110A) mutants of hSLC2A9 
WT. The forward and reverse primers for the 
I335V mutant were 5‘- GTG GCC TCA ATG 
CAG TTT GGT TCT ATA CCA ACA GC -3‘and 
5‘ - GCT GTT GGTATA GAA CCA AAC TGC 
ATT GAG GCC AC – 3‘ (17); for the W110A 
mutant were 5'-CT CTG ACT TTG CTC GCG 
TCT GTG ACT GTG TCC-3' and 5' - GGA CAC 
AGT CAC AGA CGCGAG CAA AGT CAG AG 
- 3'; and for theW110F mutant were 5'- CCC AGA 
CAC TCT GAC TTT GCT CTT CTC TGT GAC 
TGT GTC C  -3' and 5'- GGA CAC AGT CAC 
AGA GAA GAG CAA AGT CAG AGT GTC 
TGG G -3' (Sigma Aldrich Canada). These 
plasmids were transformed into Escherichia coli 
DH5α competent cells for DNA propagation.  
 mRNA Preparation and Xenopus laevis 
Oocyte Microinjection -- mRNA preparation and 
microinjection were performed as previously 
described (13,14). In brief, plasmids containing 
hSLC2A9 WT and its I335V, W110A and W110F 
mutants were linearized with NheI and transcribed 




Individual adult female X. laevis oocytes were 
separated by collagenase and manually 
defoliculated before injection.  Isolated oocytes 
were injected with 10-20 nL (20 ng) mutant 
plasmid mRNA and incubated in modified Barth‘s 
medium (MBM), 88 mM NaCl, 1mM KCl, 0.33 
mM Ca(NO3)2, 0.41 mM CaCl2, 0.82 mM MgSO4, 
2.4 mM NaHCO3, 10 mM Hepes, 2.5 mM sodium 
pyruvate, 0.1 mg/ml penicillin and 0.05 mg/ml 
gentamycin sulfate, (pH 7.5) for 4 days at 16–18
o
C 
prior to functional assays. All chemicals were 
obtained from Sigma-Aldrich unless otherwise 
stated. The same volume of water was injected 
into oocytes as a control. The concentration of 
mRNA was determined using a Nano Drop 1000 
Spectrophotometer V3.7 (Thermo Fisher 
Scientific, USA). 
 Radiotracer flux experiments -- All 





C labeled urate 
(Moravek) was used in flux and efflux 
experiments to test the urate handling 
abilityofhSLC2A9 WT, I335V, W110A and 
W110F mutants. Radioactivity was measured with 
a Beckman LS6500 liquid scintillation counter 
(Fullerton, CA, USA). Experiments were 
performed as previous studies described (13,17).  
 Urate kinetics --Urate transport was 
measured by incubating oocytes with 200 µL urate 
solution ranged from 100 µM to 5 mM. Oocytes 
were incubated for 20 min, which was determined 
as the linear portion of the urate uptake. The 
transport reaction was stopped by washing with 
ice cold MBM; then individual oocytes were 
placed into scintillation vials for uptake activity 
measurement. Uptake activity was corrected for 
non-specific activities measured from control 
water injected oocytes from the same batch for 
each experiment. 
 Trans-stimulation of urate uptake-- 
Oocytes were loaded with substrates, D-fructose, 
urate and D-fructose by preincubation for 1 hr. 
Preloading was terminated by washing the oocytes 
with fresh MBM. Preloaded oocytes were then 
used to perform 
14
C urate uptake experiments as 
described above.  
 Electrophysiology experiments --
Experiments were conducted using the two-
microelectrode voltage clamp (TEVC) technique 
with a GeneClamp 500B (Molecular Devices Inc. 
Sunnyvale, CA, USA).  Sodium containing 
transport medium (STM), 100 mM NaCl, 2 mM 
KCl, 1 mM CaCl2, 1 mM MgCl2, 10 mM Hepes, 
pH 7.5 with Tris Base) was used to perfuse 
oocytes to obtain a base line current before adding 
experimental substrates. Urate induced current (1 
mM urate in standard STM) and urate kinetics 
analysis (with urate concentration ranging from 
0.05 to 5 mM, added to STM) was performed 
using a Gap-free protocol. Individual oocytes were 
clamped at -30mV and super-perfused with 
different concentrations of urate for 30 seconds 
(range from 0.1 to 5 mM) followed by a 1 minute 
wash with urate free buffer in between. Data were 
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(previous analysis had shown that using the 
plateau following the peak provided identical 
kinetics). Data were expressed in the form of 
urate-induced mean current ± SEM, where SEM 
stands for standard error of the mean. Current-
voltage (I-V) curves were measured with a RAMP 
protocol in which the voltage was changed from -
120 to 60 mV for a 3 second period. I-V curves 
were RAMP at the peak of the urate induced 
currents. A Digidata 1320A converter and 
pClamp8 (Axon Instruments, Union City, CA) 
were used to collect and analyze data. Then, we 
performed the Gap-free protocols to compare 
inward mean peak currents using either STM wash 
buffer or fructose containing STM buffer after 
oocytes were pre-incubated in situ with 1 mM 
urate for 1 minutes. The trans-acceleration 
measured with TEVC assumed that the inward 
currents induced by washing the oocytes with 
STM are urate induced. That is, these currents 
were induced when urate moved out of the oocyte 
(downward facing peak current value, see Fig. 4A 
and 4B).  
 Biotinylation --Biotinylation and Western 
blot analyses were carried out to measure the 
protein expression level of each isoform based 
upon a previously published protocol (19) with 
modification. Oocytes were washed three times 
with PBS (pH 8.0); then, they were incubated in  2 
mM Sulfo-NHS-LC-Biotin (Pierce) at room 
temperature  for 30 minutes. The reaction was 
stopped by washing with quenching buffer (192 
mM Glycine and 25 mM Tris-HCl in PBS, pH 
7.5). Oocytes were then lysed with RIPA buffer 
(150 mM NaCl, 1% Triton-X-100, 1% 
deoxycholic acid, 0.1% SDS, 1 mM EDTA, 10 
mM Tris-HCl, pH 7.5). Lysates were incubated 
with streptadvidin (Pierce) at 4
o
C overnight. On 
the next day, beads with bounded protein were 
spun down gently. Biotinylated proteins were 
resuspended using SDS sample buffer  and 
subjected to SDS-PAGE. Proteins from SDS-
PAGE were transferred to nitrocellulose 
membranes and blocked with 3% milk in PBST 
(0.05% Tween 20 in PBS). After blocking, the 
membrane was probed with primary hSLC2A9 
antibody (Cedarlane, Canada) and anti-rabbit 
secondary antibody (Abcam, Cambridge, MA, 
USA). Protein quantification was by measuring 
the band intensities using Image 
J(http://imagej.nih.gov/ij/). 
 Immunohistochemistry--
Immunohistochemistry was used to determine 
protein expression in X. laevis oocyte membranes. 
Oocytes were washed with Phosphate Buffer 
Saline (PBS; 137 mM NaCl, 2.78 mM, KCl, 4.3 
mM Na2HPO4, 1.5 mM KH2PO4, pH 7.4), then 
fixed in 3% Paraformaldehyde (PFA) for 15 
minutes at RT. After fixation, oocytes were 
washed with 50 mM NH4Cl and permeabilized 
with 0.1% Triton. X. Oocytes were then blocked 
with 2% Bovine Serum Albumin (BSA) for 30 
minutes followed by incubation with primary 
hSLC2A9 antibody in blocking buffer for 1 hour 
at RT, and then with secondary antibody, Alexa 
488 (Invitrogen, USA). After incubation, oocytes 
were mounted using Vectashield mounting 
medium (Vector Laboratories, Inc. Burlingame, 
CA USA) on slides with secure-seal spacers. 
Protein expression was determined by Wave FX 
confocal microscopy (Quorum Technologies, ON, 
Canada) of the fluorescent secondary antibody.  
 Data analysis --Graphpad 5.0 was used to 
analyze all the data. Urate kinetic data was fitted 
using non-linear regression. Current-voltage (I-V) 
curves were graphed in X-Y plots. Trans-
acceleration data was analyzed by One-way 
ANOVA for the flux studies and Student unpaired 
t-test in TEVC studies. Significant values were 
accepted when p<0.05. Biotinylation of protein 
expression level data was compared using 
arbitrary units of band intensity.  
Homology modeling --The three-
dimensional models of the human 
transportersSLC2A5 and SLC2A9 were built 
using the I-TASSER server, which is based on ab 
initio/threading methods (20) and choosing the 
crystal structure of human glucose transporter 
SLC2A1 (PDB ID 4PYP) as the preferred 
template. The sequence identity/similarity between 
SLC2A1 (orSLC2A5) and SLC2A9 are 
28/49%(or29/59%). The server generated 5 
models with the best model for each target 
selected based on their C-scores (-1.2) 
implemented in I-TASSER. The score is 
calculated based on the significance of threading 
template alignments and the convergence 
parameters of the structure assembly simulations. 
The stereochemical quality of the model was 
assessed with Molprobity and it showed that 92% 
of the residues are in the most favourable regions 
of the Ramachandran plot for both molecular 
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with Clustal Omega (22) with figures created in 
ESPript 3.0 (23) and The PyMOL Molecular 
Graphics System, Version 1.5.0.4 Schrödinger, 
LLC.  
RESULTS 
Urate kinetics --1) Flux studies. After 
determining that urate transport mediated by WT 
hSLC2A9 and its I335V, W110A and W110F 
mutants were similar at 0.1 mM substrate 
concentration (data not shown), the kinetics for 
both mutants were then fully characterized. As 
shown in Figures 1A and 1B, the data indicate that 
the Michaelis-Menten like kinetics for urate are 
similar for both the WT and the I335V mutant. 
WT hSLC2A9 has an average VMAX of 
981.9±136.5pmol/oocyte/20min with a KM of 
4.5±11.6 mM; I335V has a VMAX of 937.7±278.1 
pmol/oocyte/20min, KM of 6.6±3.1mM;W110A 
has an average VMAX of 108.5±11.1 
pmol/oocyte/20min, KM of 0.3±0.1 mM; and 
W110F has an average VMAX of 355.6±61.9 
pmol/oocyte/20min, KM of 1.7±0.7 mM. This 
indicates that urate transport by the I335V mutant 
is very similar to the WT. The W110A mutant, on 
the other hand, has higher affinity and lower 
transport capacity compared to WT. W110F show 
a intermediate VMAX and KM between W110A and 
WT hSLC2A9. 
2) Two-Electrode Voltage Clamp 
Experiments (TEVC). Because urate transport by 
WT hSLC2A9 is electrogenic (13,14), we also 
used the TEVC method to further investigate how 
hSLC2A9 and its mutants transport urate. A 
representative trace from the actual recording 
obtained with WT hSLC2A9 is shown in Figure 
2A. We clamped a single oocyte at a holding 
potential of -30 mV, then perfused the oocyte with 
different concentrations of urate followed by a 1 
minute wash with STM. We then measured the 
mean induced outward current Data were collected 
at the peak of each urate induced current. Fig. 2B 
shows that urate transport by hSLC2A9 WT and 
its mutants displayed classical Michaelis-Menten 
kinetics. This confirms that all these proteins have 
only a single binding site for urate. Also, we can 
conclude that hSLC2A9 WT and I335V transport 
urate in the same way because they have very 
similar kinetic constants, Fig. 2C; (WT: 
VMAX=433.4±21.5nA, KM=1.9 ±0.2 mM, I335V: 
VMAX=451.0±26.5nA, KM=2.2±0.3 mM). However, 
the W110A and W110F mutations shift the urate 
kinetic curve to the right with a significantly 
smaller VMAX (115.0±5.8 nA and 158.9±14.5 nA), 
and KM (0.7±0.1 mM and 1.0±0.3mM), suggesting 
that this tryptophan residue may play a key role in 
substrate preselection or binding.  
 I-V curve using TEVC -- In addition, we 
further investigated the protein function using 
current-voltage (I-V) curves as shown in Fig. 2D 
using a RAMP protocol. I-V curves were RAMP 
at the peak of the urate induced currents. The 
voltage was progressively changed from -120 to 
60 mV within a 3 second time period. Current 
recordings were filtered and current values at 20 
different voltages from -120 to 60 mV were 
shown. As indicated in Fig. 2C, urate transport 
showed a quasi-linear relationship with the 
membrane potential   in the range from -120 mV 
to 60 mV, indicating that urate transport is driven, 
but not gated by the voltage. The I-V curves of 
WT and I335V are similar; however, the I-V curve 
of W110A shows that urate induced current is 
smaller than WT similar to the urate kinetics 
analysis, and the curve of W110F indicates the 
urate induced current is in between those recorded 
for WT and W110A. Overall, this suggests that the 
ability of SLC2A9 to bind and translocate urate is 
driven by the membrane potential. 
 Urate/ hexose trans-stimulation: --1) 
Isotopic flux studies. hSLC2A9 was originally 
reported to be a high affinity - low capacity hexose 
transporter and subsequently a high capacity urate 
transporter. It was also noted that hexoses can 
trans-accelerate urate uptake into oocytes (13,14). 
Thus, we further examined the effect of trans-
stimulation of urate transport by hexoses mediated 
by hSLC2A9 and its I335V, W110A and W110F 
mutants. Fig. 3A shows urate flux rates compared 
with their control experiment using the non-
transported L-glucose. Fig. 3B shows the 
normalized percentage of the trans-stimulation 
effect of both fructose and urate relative to the 
control, L-glucose. These result indicate that urate 
trans-stimulates urate uptake in all cases (One-way 
ANOVA, p<0.05) and that fructose trans-
stimulated urate uptake mediated by WT and 
W110F hSLC2A9 (One-way ANOVA, p<0.05) 
but not by the I335V or W110A mutants (One-
way ANOVA, p> 0.05, n≥4).  
 2) Using TEVC Fig. 4A and 4B show 
representative traces of urate induced current 
mediated by hSLC2A9 WT, I335V, W110A, and 
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protocol in which the oocytes were clamped at -30 
mV and incubated with 1mM urate for 1 minute. 
These traces clearly indicate that the inward 
current increases in the presence of extracellular 
fructose in oocytes expressing WT and W110F but 
not in those expressing I335V and W110A. Fig. 
4C is a bar graph showing the peak mean inward 
currents. Again, results showed that increased 
inward currents were observed in WT and W110F 
expressing oocytes when extracellular fructose 
was present (Fig. 4A and 4B, n≥18, unpaired t-
test, p<0.05). In contrast, no stimulation by 
fructose was seen in I335V and W110A 
expressing oocytes (n≥18, unpaired t-test, p>0.05). 
 Qualitative and quantitative protein 
expression -- Qualitative analysis of hSLC2A9 and 
its I335V, W110A and W110F mutant protein 
expression in the plasma membranes of X. laevis 
oocytes was determined using 
immunohistochemistry as shown in Fig. 5A. 
hSLC2A9 WT, I335V,  W110A and W110F 
proteins were expressed in the oocyte membrane, 
whereas water injected oocytes showed no 
detectable protein expression (n=3). Membrane 
proteins of all isoforms were also detected by 
biotinylation indicated in Fig. 5B. Indicated in 
Fig. 5C, protein expression levels were almost 
identical in both hSLC2A9 WT and the I335V 
mutant. Although the total expression protein 
levels seem slightly less in W110A and W110F 
compared to the WT, these differences are not 
statistically significant. The membrane protein 
expression levels are all proportional to the their 
total protein levels.  (n≥6, One-way ANOVA, p 
>0.05).  
Structural analysis of SLC2A9 using 
homology modeling--To provide structural insight 
into these critical residues, a model of the human 
SLC2A9 transporter was generated based on the 
human glucose transporter SLC2A1 (PDB ID 
4PYP) (16). The accuracy of homology model is 
dependent on the template sequence identity 
(>30%) or the quality of the alignment between 
the target and template. Fortunately for membrane 
proteins, even at low level of template sequence 
identity, accurately model prediction is possible. 
The membrane environment imposes topological 
constrains on the relative orientations of helices, 
which limit structural diversity available to 
families of membrane proteins. SLC2A1 and 
SLC2A9 share 28% sequence identity and a high 
degree of similarity, 49%. Phylogenetic 
comparison reveal three classes within the GLUT 
clade, with hSLC2A1, a class 1 GLUT, and 
hSLC2A9, a class II GLUT, having similar 
predicted topologies (24). Due to such high 
homology the template treading alignment score 
was remarkably high as indicated by the 
normalized Z-score of 3.4. Alignments with a 
normalized Z-score > 1 reflects a confident 
alignment and most likely have the same fold as 
the query protein. Furthermore, I-TASSER 
confidence score (C-score) for the derived 
SLC2A9 model is also in the higher range (1.2). 
Confidence values higher than 1 indicates that the 
overall derived structural homology model is 
likely accurate, that is, that deviation between 
derived homology model and the template 3D 
structure is low (20). 
The SLC2A9 model has 12 
transmembrane segments and represents the 
inward facing conformation (Fig. 6A). Fig. 6B and 
6C show both views from intracellular face and 
extracellular face of the model. These 12 TM 
segments are organized into two structural repeats, 
TM1-6 and TM7-12, related by a pseudo two-fold 
inversion axis parallel to the membrane bilayer, 
yielding a 6+6 inverted repeat fold. The 
transmembrane domains 1, 2, 4, 5, 7, 8, 10, 11 line 
the central transport cavity and 3, 6, 9, and 12 
form the outer helices as seen in Figure 6A. 
Furthermore, we see evidence of an intracellular 
helical bundle (ICH) on the cytoplasmic face of 
the transporter (Figs. 6A). Crystal structures of 
SLC2A1, XylE (25) and GlcP (26) suggest that all 
of the MFS transporters have an ICH located at the 
cytoplasmic face that is thought to affect the 
conformational change between inward- and 
outward-facing conformations (27).  
 
 A comparison of the SLC2A9 model with 
the SLC2A1 structure indicates an excellent 
structural agreement with an r.m.s.d. of 0.49 Å 
over 442 C-alpha atoms excluding variable N and 
C terminals. A central amphipathic pore 30 Å deep 
is formed by two interior pairs of symmetry-
related helices — TM1 and TM4, and TM7 and 
TM10 — that are surrounded by an outer ring of 
helices, TM2, TM5, TM8 and TM11. A higher 
r.m.s.d. of 0.32 Å is obtained when the pore region 
of SLC2A9 is aligned with those in SLC2A1, 
which underlies functional conservation. Both 
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non helical hinge-region. This structural element 
plays a significant role in conformational changes 
during substrate transport. Main structural features 
of SLC2A9 and SLC2A1 are very similar, 
however the size of this hinge region in SLC2A9 
different than SLC2A1 - smaller for TM7 and 
larger for TM10. These subtle differences can 
account for isoform specific transport properties. 
Fig.6D shows that in SLC2A9, I335 is located in 
TM7 and faces away from the binding and 
translocation pore, in contrast to our earlier 
hypothesis(18).  This residue interacts with two 
residues in helix 10 to form an intricate 
hydrophobic patch. Conversion of this residue to 
valine disrupts these interactions (Fig. 6E). Since 
substitution of this residue in SLC2A5 has also 
been shown to affect fructose and urate transport 
(17), SLC2A5 was also modeled based on 
SLC2A1, with models being made of the 
equivalent isoleucine (Ile) to valine (Val) 
mutations (Fig. 6F and 6G). The SLC2A5 shares 
41.7% sequence identity and 56.1 similarity with 
SLC2A1 (28), resulting in a model with an r.m.s.d. 
of 0.81Å. As with SLC2A9, a mutation of Ile to 
Val disrupts important hydrophobic linkages of 
TM7 with helices at the outer edge of the 
transporter. 
Structural analysis of the W110 residue 
indicates it is located on TM2, and the indole ring 
of the residue faces towards the substrate 
recognition and translocation pore. We compared 
side chain orientations of key residues in all 5 top 
scoring models. I335 side chain position was 
nearly identical in all the models however W110 
adopted multiple orientations within the pore (Fig. 
7). The kinetic data suggest that this residue may 
be involved in substrate binding, as urate transport 
is greatly reduced when this residue is mutated to 
alanine. 
DISCUSSION 
 Hydrophobic residues are well known 
determinants in protein structure-function 
relationships. Residues such as isoleucine, valine, 
leucine, and phenylalanine, are often clustered 
within active sites (29). For example, SLC2A1 has 
a leucine (L279) within the most conserved motif 
‗QLS‘ in GLUTs adjacent to the postulated 
‗bottle-neck‘ region of the substrate transport 
pathway (30) and valine165 is also predicted to be 
located near the exofacial surface of the substrate 
binding site (31). Subsequently, Manolescu et al 
proposed that an isoleucine in TM7 is a critical 
determinant of substrate selection in class 2 
hSLC2As (5, 7, 9 and 11). They found that 
substituting an isoleucine for valine at the 
equivalent position within these proteins 
significantly reduces or abolish fructose transport, 
while not affecting glucose fluxes (17). Dietvorst 
et al. also demonstrated that isoleucine 374 in 
TM7 of Snf3 is essential for fructose sensing in 
yeast Saccharomyces cerevisiae, but does not 
affect their glucose sensing (32). Given that 
hSLC2A9 also transports urate, this study was 
designed to examine the effect of this I-V 
substitution on urate transport and the trans-
stimulation behaviour between hexoses and the 
organic anion.  In addition, our earlier prediction 
that isoleucine or valine might form a hydrophobic 
interaction across the translocation pore with a 
tryptophan in TM2 led us to also investigate the 
role of this residue (W110). 
 
The electrogenic property of urate 
transport by hSLC2A9 allows further 
characterization of urate fluxes by measuring the 
urate induced current. The representative trace 
from the Gap-free protocol of WT hSLC2A9 
expressed oocytes shows a typical urate induced 
current trace, in which a fast occurrence of 
outward current is followed by a slow decline to a 
plateau (Fig. 2A). This observation was previously 
reported in both Bibert et al's and our studies (14, 
33). We propose that there must be a rapid 
accumulation of the entered urate in the proximity 
of the inner face of the oocyte surface membrane. 
Previous studies have reported that this 
phenomenon corresponds to the presence of a so-
called ―unstirred layer‖ due to the slower  urate 
diffusion away from the membrane than  the rate 
of urate entry (34). This leads to a decreased 
chemical gradient/driving force for urate entry, 
thereby resulting in a decreasing current from its 
peak value. In fact, this reduced current at the 
plateau must be the net result of two opposing 
currents: influx of extracellular urate and efflux of 
urate from the unstirred layer,  which represents a 
steady state condition of the unstirred layer.  
However, upon extracellular urate withdrawal, 
only the latter is present, corresponding to the 
observed undershooting currents, which quickly 
vanished, likely due to exhaustion of the urate 
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concept of the presence of an accumulated urate 
proximal to the inner face of the surface 
membrane is in agreement with the time course of 
these events.  
The urate kinetics and current-voltage (I-
V) curves determined by TEVC matched the 
isotopic flux confirming that both WT hSLC2A9 
and the I335V mutant transport urate similarly 
(Fig. 1A and 2B). However, it is not so easy to do 
a direct comparison of the transport properties 
from these two methods due to the different 
conditions achieved using the two techniques. 
(Fig. 1B and 2C) In the flux study, the oocyte 
membrane potential was not clamped; thus, entry 
of negatively charged urate into an oocyte should 
have quickly hyperpolarized the membrane 
potential, from an initial value of around -30 mV 
to a value of -50 mV or so, depending on the 
magnitude of the influx (14). The hyperpolarized 
voltage, representing a reduced driving force, thus 
decreased urate entry. This effect would increase 
as the urate concentration employed rose.  In 
contrast, the oocyte membrane potential was held 
constant at -30 mV, by a gap-free protocol during 
a TEVC experiment; hence, the chemical gradient 
becomes the dominant driving force for urate 
transport into the oocytes. Thus, the urate entry 
rate for a given concentration will differ between 
the two protocols. Nevertheless, one conclusion 
we could draw from the I-V curve experiments is 
that the more the membrane potential is 
depolarized, the higher the urate influx. (Fig. 2D) 
This confirms our previous suggestion that the 
membrane potential is a driving force for 
hSLC2A9 to bind and translocate urate.  
 
The Role of Isoleucine 335 
 Our flux trans-acceleration measurements 
indicate that both intracellular fructose and urate 
are capable of stimulating urate uptake into WT 
hSLC2A9 expressing oocytes. This could be 
explained by the Simple Carrier Model theory in 
which reorientation of an empty carrier from one 
side of the membrane to the other is the rate 
limiting step (35,36). That is, when a substrate is 
presented on the trans side of the membrane it will 
be energetically more favourable for the substrate-
protein complex to reorient from the trans side to 
the cis side. A more recent study on another MFS 
protein, the lactose permease, LacY, also 
demonstrated that the empty protein is the rate 
limiting step for sugar binding and transport. 
Smirnova et al. found that sugar binding is 
energetically favourable for increasing the open 
probability of LacY to the periplasm (37). We 
observed a similar phenomenon in our trans-
acceleration experiments in which both preloaded 
fructose and urate (trans) simulate 
14
C urate 
hSLC2A9 mediated transport into (cis) the 
oocytes. Our data also suggest that I335 of 
hSLC2A9 is necessary for urate/fructose trans-
acceleration to occur during transport (Fig. 3). 
Fructose/urate stimulation was lost in the I335V 
mutant, while the urate/urate exchange remained 
unchanged. The reduction of fructose transport 
activity in the I335V mutant could thus lower the 
energy for the mutant transporter to reorient from 
the intracellular to extracellular side. 
Consequently, the trans-accelerating effect of 
fructose was lost. These data provide additional 
evidence for a role of I335 in fructose permeation 
in a class II hSLC2A protein, but that I335 is not 
involved in urate transport in hSLC2A9 (Fig. 1A). 
Urate kinetics and urate/urate trans-acceleration 
were unaffected in I335V compared to the WT 
hSLC2A9, which supports our previous 
conclusion that fructose and urate share the same 
transporter but they interact with the translocation 
pathway quite differently.  
Until now, hSLC2A9 is the only Class II 
glucose transporter in which trans-acceleration 
behaviour has been reported. Other members of 
Class I, like hSLC2A1 and 3 but not hSLC2A2 
and 4, have also been characterized for their 
ability to exchange hexoses in both oocyte and 
mammalian cell studies (38-41). Through the 
construction of chimæras between hSLC2A1 and 
4, Vollers and Carruthers found that TM6 of 
hSLC2A1 contains residues necessary for trans-
acceleration with glucose-glucose exchange (38). 
 In the TEVC trans-stimulation study, we 
used the Gap-free protocol to detect urate efflux 
elicited inward currents by perfusing oocytes with 
fructose and fructose-free buffer. After preloading 
the oocytes with urate, we observed that 
extracellular fructose increased the urate elicited 
inward current with WT hSLC2A9, but not with 
the I335V mutant (Fig. 4). Thus, our study has 
shown that I335 in TM7 is an essential residue for 
fructose to accelerate urate movement in the 
opposite direction. This confirms that I335 plays 
an important role in the ability of hSLC2A9 to 
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Structural Modelling of hSLC2A9 
An early computer model of hSLC2A7 
based on the GlpT structure (42), Manolescu et al. 
suggested, that the isoleucine in the equivalent 
position (I314) appeared to be located on TM7 
within the extracellular vestibule facing the 
translocation pore. Consequently, they suggested 
that a hydrophobic residue at that site could either 
interact directly with substrates as they entered the 
pore or there could be a hydrophobic interaction 
across the pore with W89 on TM2 (18).  
However, our revised model of hSL2A9 
based upon the recent crystal structure of human 
SLC2A1 indicates that this residue is not oriented 
towards the central pore. Instead, it appears to 
interact with residues on the adjacent TM 10 via 
an intricate hydrophobic network (Fig. 6D). 
Notably, our new hSLC9A model provides a 
higher degree of accuracy, given that both 
SLC2A1 and SLC2A9 are in the same transporter 
classification, from the same species, resulting in a 
considerable increase in sequence similarity with 
SLC2A1 compared to GlpT. The single amino 
acid changes in SLC2A9, I335V, decreased 
fructose transport, but not glucose. A structural 
model for the mutant SLC2A9-I335V was also 
generated, in which we observed an apparent loss 
of the hydrophobic contacts observed with 
isoleucine in the identical position (Fig. 6E). The 
structural model strongly suggests that via its 
hydrophobic network, I335 affects the rigid body 
movement of one of the two six-helix bundles, and 
subsequently the orientation of helix 7 in the 
translocation pore of the transporter. The 
alternating access model developed for MFS 
transporters proposes that the two six-helix 
bundles form the translocation pore and moving 
through an occluded state to provide access of the 
substrate binding pocket to one side of the 
membrane or the other (38). This central 
isoleucine residue may promote a more rigid 
coupling of helix 7 to the other members of its 
helical bundle altering how it faces the 
translocation pore and subsequently influencing its 
ability to bind fructose. In the I335V mutant this 
interaction appears to be weakened changing the 
orientation of TM7 and hence the protein then 
loses its ability to bind fructose.   
A molecular model of SLC2A5 was also 
generated based on the SLC2A1 crystal structure 
to gain insight into how this residue influences 
substrate specificity among other family members. 
In the SLC2A5 model, this isoleucine promotes a 
more complex interaction with the surrounding 
helices 9, 10 and 12 –essentially linking helix 7 to 
its half of the transporter (Fig. 6F). Similarly, 
when we modeled the same substitution in 
SLC2A5 the hydrophobic network was again lost 
(Fig. 6G). Together these observations suggest 
that this hydrophobic residue plays a crucial role 
in altering the different conformational states in 
the alternating access model and subsequently 
substrate specificity.   
 
The Role of Tryptophan 110. 
 Our new model also rules out an 
interaction of W110 with I335 but suggests that 
W110 has a role in regulating substrate transport. 
As mentioned above, earlier modeling studies of 
hSLC2A7 suggested that W85 in TM2 (equivalent 
to W110 in hSLC2A9) might form a hydrophobic 
interaction with I314 across the pore in TM7 
serving as a pre-selection site in regulating 
fructose transport through hSLC2A7 (18). Our 
new model indicates interactions of W110 in the 
central pore, and substitutions lead to altered 
transport further suggesting a role in substrate pre-
selection. However at this stage it is unclear 
whether these observed effects are due to direct 
interaction with substrates or structural changes. 
      Such pre-selection mechanisms have also been 
observed for other transporters, early crystal 
structures of LacY and SGLT1 showed that the 
indole ring of tryptophan/tyrosine is a common 
feature of sugar-binding proteins, where the 
primary hydrophobic interaction occurs between 
sugar and the sugar binding sites (43,44).   
In the glucose transporter 1 (SLC2A1), 
tryptophans in TM10 and TM11 are known to be 
responsible for glucose transport activity and 
substrate binding (45,46). Also, a docking study 
indicated that W65 formed a direct interaction 
with the C6 of glucose (47). In addition, a 
tryptophan residue mutation had been identified in 
another urate transporter, hSLC22A12, as a major 
cause in hypouricemia in Japanese patients (48). 
These observations support the view that W110 in 
hSLC2A9 could also be interacting with urate 
and/or fructose directly. Indeed when mutated to 
alanine (W110A) urate transport was affected 
substantially (Fig. 1A). The KM for urate uptake 
was reduced indicating an increased affinity for 
the substrate while at the same time the VMAX was 
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changes in urate kinetics the urate/urate exchange 
was still present (Fig. 3).  
 The effect on urate transport could 
therefore result from a loss of a direct interaction 
between W110 and the substrate or be a 
consequence of an altered structure of the protein.  
In the latter case, the time spent in the occluded 
state during the conformational change between 
the outward and inward facing states could be 
affected. W110A, has very similar KM in both 
TEVC and flux studies, suggesting that varying 
the intracellular membrane potential did not affect 
how W110A handles urate transport. We were also 
interested in determining whether urate and 
fructose transport would still be maintained when 
W110 is mutated into another aromatic residue. 
Therefore, we constructed a third mutant of 
hSLC2A9, tryptophan 110 into phenylalanine 
(W110F). We observed that W110F partially 
reduced urate transport with a lower VMAX and 
smaller KM compare to WT; whereas these values 
are higher when compared to W110A (Fig. 1). 
This indicated that W110F has higher capacity and 
lower affinity for urate when compare to W110A. 
In addition, the trans-stimulation experiment data 
demonstrated that both urate/urate and 
urate/fructose exchange were maintained in 
W110F. This indicated that the aromatic ring 
structure is not only important for urate transport, 
but also fructose transport at this W110 position of 
hSLC2A9 (Fig. 3 and 4).  
These data support our hypothesis that 
either these electronic rich aromatic rings are 
forming direct interactions with the charged 
substrates during transport, or they are involved in 
maintaining protein structure by interacting with 
other residues in the protein. With a partially 
altered the ring structure, W110F maintains the 
primary hydrophobic interaction with the 
substrates; thus, it is still able to transport both 
urate and fructose. In contrast, W110A has no 
aromatic ring in the residue; hence, it was not able 
to sense changes in the ionic environment and 
influence the urate/fructose transport properties. 
All these data imply that the bulky side chain of 
tryptophan is essential for urate transport in 
hSLC2A9.   
 Additional analysis of structural models 
generated using I-TASSER indicated a 
considerable degree of flexibility for the W110 
residue in the pore region (Fig. 7) again 
suggesting that it may play a role in substrate 
binding, selectivity or occlusion. Transition of 
SLC2A9 from an outward facing to an inward 
facing conformation through an occluded state is 
possibly associated with conformational changes 
in the inner pore region, which might involve the 
repositioning of the W110 side chain. Fig. 7 
suggests that the indole ring of tryptophan could 
act as a lid between the protein‘s central cavity 
and the extracellular face, which could serve as a 
‗thin gating element‘ similar to that proposed for 
other sugar transporters, like vSGLT (49). MFS 
transporters are known to have several 
mechanisms for substrate occlusion and 
permeation. Common denominators in all these 
structures include an extracellular facing ―thin 
gate‖ that plays a role in providing access to the 
primary substrate binding site. We propose W110 
could play such a role in controlling access to the 
primary binding site and could be one of the 
residues forming a ‗thin gate‘. In addition, it could 
also serve as a closure to prevent urate escaping 
from the binding site before the protein changed 
from an outward to an inward conformation 
avoiding a futile cycle. However, several crystal 
structures are needed to determine the precise 
nature of the role of W110. 
Although many studies indicate that 
hSLC2A9 is primarily a urate transporter, its 
ability to transport hexoses should not be ignored. 
Our studies have demonstrated hSLC2A9 cannot 
only transport both hexoses and urate, but can also 
exchange the two different types of substrate. 
There is an obvious implication in that hSLC2A9 
could serve as an excellent candidate in regulating 
both blood sugar and urate in humans. For 
example, Emmerson pointed out that when 
fructose is given orally it causes an increase in 
urate excretion in the urine of children (50). 
hSLC2A9 is expressed in both the proximal 
convoluted tubule and collecting duct in human 
kidney nephrons, sites where both sugars and urate 
are handled (51-54). Therefore, understanding the 
mechanism of how hSLC2A9 can exchange 
hexoses and urate in the human kidney will be 
valuable for developing new treatments for 
patients with hyperuricemia or hyperglycemia.  
 In summary, this study has further 
demonstrated that the hydrophobic residues, 
isoleucine 335 and tryptophan 110, of hSLC2A9 
are important residues influencing both hexose and 
urate transport. Future studies of hSLC2A9 


































Role of hydrophobic residues in SLC2A9 
11 
 
even better understanding of urate transport and its 
regulation and hence the causation of 
hyperuricemia. A series of crystal structures is 
needed to determine the exact roles of both 
residues within hSLC2A9. Furthermore, 
understanding the hSLC2A9 binding sites for urate 
and hexoses could help to provide a 
pharmacological basis for effective treatment of 
hyperuricemia and other related diseases, such as 
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C Urate kinetic measurements in oocytes expressing hSLC2A9. Panel A. Michaelis-
Menten curves of 
14
C urate kinetics of hSLC2A9 WT ( ) and its mutants I335V (☐) , W110A (  ), and 
W110F (  ). Urate uptake was measured by incubating protein expressing oocytes in 200 µL urate solution 
ranged from 100 µM to 5 mM for 20 minutes. Uptake activity was corrected for non-specific transport 
measured in control water injected oocytes from the same batch of oocytes. Panel B. 
14
C urate kinetic 
constants of the 3 isoforms (n =4). 
 
Figure 2. Urate induced currents in oocytes measured with Two Micro-Electrode Voltage Clamp 
(TEVC). Panel A provides a representative trace from the Gap-free protocol of WT hSLC2A9 expressed 
oocytes. Single oocytes were clamped at -30 mV and super-perfused with different concentrations of 
urate for 30 second (range from 0.1 to 5 mM) followed by a 1 minute wash with urate free buffer in 
between. Panel B. Michaelis-Menten curves of uratekinetics of hSLC2A9 WT ( ) and its mutants I335V  
(☐), W110A (   ), and W110F (  ). Data were collected at the peak of each urate induced current. Points 
represent the mean of urate induced peak outward current for each concentration. Panel C. 
14
C urate 
kinetic constants of the WT and mutant isoforms (n >15 oocytes from 3 frogs).  Panel D. Current-Voltage 
curve of 1 mMurate induced current obtained from RAMP protocol for control, WT hSLC2A9 ( ), the 
I335V (☐), W110A(   ) and W110F (  ) mutant expressing oocytes. The oocytes were clamped initially at 
-30 mV followed by voltage change instantly from -120 to 60 mV for a 3 seconds period. I-V curves were 
RAMP at the peak of the urate induced currents. (n >15 oocytes from 3 frogs). 
 
Figure 3. Trans-acceleration studies for urate uptake into oocytes preloaded with urate or fructose.  
Panel A. Trans-acceleration experiments of urate flux in the presence of intracellular substrates mediated 
by hSLC2A9 WT, I335V mutant, W110A mutant, and W110F expressing oocytes. Oocytes were 
preloaded with intracellular substrates, L-glucose (dark), D-fructose (grey) or urate (white) by 
preincubation for 1 hour. Preloaded oocytes were then washed with fresh MBM prior to performing 
14
C 
urate uptake experiments. Panel B. Bar graphs represent the percentage of each condition relative to 
control experiments (L-glucose), (n>3, One-way ANOVA, * p<0.05). 
 
Figure 4. Trans-acceleration studies of urate induced currents mediated by hSLC2A9 measured 
with TEVC. Panels A and B are representative current traces in a single oocyte expressing hSLC2A9 WT 
(upper traces), the I335V (lower traces), W110F (upper traces), and W110A  (lower traces) mutants. All 
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(left) or 50 mM D-fructose STM buffer (right). Oocytes were clamped at -30 mV and traces were 
recorded under the Gap-free protocol. Panel C; Mean urate induced inward currents were collected at the 
peak of the inward currents. hSLC2A9 WT, I335V , W110F , and W110A . Urate pre-loading oocytes 
were washed with either standard transport medium (STM, dark) or 50mM fructose containing STM (Fru, 
white). (n≥15 oocytes from 3 frogs, unpaired t-test, * p<0.05) 
 
Figure 5. Qualitative and quantitative determination of WT and mutant hSLC2A9 protein 
expression. Panel A; Representative pictures of immunohistochemistry of water injected, hSLC2A9 WT, 
I335V， W110A, and W110F mutant expressing oocytes.  Panel B; A representative picture of Western 
Blot analysis of protein expression of water injected, hSLC2A9 WT, I335V, W110F and W110A 
expressing oocytes. Total (black), Unbound (grey), and biotinylated (white) proteins of hSLC2A9 WT, 
W110F, W110A were loaded onto one 10-well SDS-PAGE gel; whereas proteins of I335V were loaded 
on a separated gel.  Panel C. Quantitative analysis of protein expression. Data were calculated from band 
intensities obtained from Image J and use a formula: Biotinylated protein = Total protein - Unbound 
protein. Protein expression levels shown as bar graphs with arbitrary units. (n≥6, One-way ANOVA 
among the three biotinylated proteins, p>0.05).  
 
Figure 6. Molecular model of the human SLC2A9 & SLC2A5 transporters comparing possible 
hydrophobic interactions. Panel A; Cartoon representation of the molecular homology model of the 
hSLC2A9a based on the human SLC2A1 crystal structure (4PYP.pdb). The twelve transmembrane 
helices are labeled. Panels B and C show views from the intracellular face and extracellular face. The 
intracellular face contains the conserved intracellular helical bundle. Panel D. Potential interactions of 
I335 indicate a hydrophobic network with residues within TM 10, thus linking the critical TM7 (coloured 
in orange) to one half of the transporter. Panel E; Structural model of the mutant SLC2A9 I335V was 
generated that demonstrates the intricate linkage to helix 10 is disrupted when I335 is converted to Val. 
Panel F; In SLC2A5 Ile296, equivalent of Ile335 in SLC2A9, forms an even more extensive hydrophobic 
cluster with neighbouring residues at TM10 and TM12, Panel G; Structural model of the mutant SLC2A5 
I296V, highlights the loss of the hydrophobic network, which subsequently leads to alteration in substrate 
specificity. 
 
Figure 7: Analysis of Tryptophan 110 orientation within the translocation pore of hSLC2A9. A 
cartoon representation of the extracellular face of two SLC2A9 homology models, with the two halves of 
6 helical bundles colored in green and purple, indicate that the W110 residue is located within the 
substrate translocation pore of the transporter. Furthermore, it was noted among the molecular models 
generated, W110 was observed in different orientations within the pore suggesting a possible role of 
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